2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

4995 CEBPA n-terminal frameshift mutation promotes multi-drug chemoresistance via the AMPK-autophagy axis in acute myeloid leukemia

Ruoyang Shao, MD, PhD, Rui Wang, N/A2, Fang Dai3, Yuxin Bai4, Fen Huang5, Na Xu6, Zhiping Fan7, Yu Zhang8, Sijian Yu9, Pengcheng SHI10, Hui Liu11, Hua Jin12, Jing Sun13, Xi Xu14, Qifa Liu, MD15, Xuan Li, PhD16
1 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
3 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
4 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
6 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
8 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
9 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
10 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
11 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
12 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
13 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
14 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
15 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
16 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

CEBPA mutations are found in ~10% newly diagnosed acute myeloid leukemia (AML) patients. CEBPA contains 3 transactivation domains (TAD) and 1 basic leucine zipper domain (bZIP). Previous studies have demonstrated different CEBPA mutation types and sites have different impact on outcomes and treatment responses in AML, while the mechanism remains unclear. In this study, we explored the underlying mechanisms of the different clinical manifestations between AML patients with CEBPA N-terminal frameshift mutations and bZIP inframe/double mutations.

Bone marrow samples were collected from a total of 28 newly diagnosed AML patients with CEBPA mutations for single-cell transcriptome sequencing (scRNA-seq), including 10 with N-terminal frameshift mutations (NM), 16 with bZIP inframe mutations or double mutations (CM), and 2 with other CEBPA mutations. Leukemia cells were defined using a previously reported machine learning-based algorithm and were subsequently clustered into 8 clusters: C0 – C7. Compared to CM samples, leukemia cells in the NM samples have significantly higher proportion of C5 and lower proportion of C4 cells, which were supported by deconvolution results from the BeatAML, TCGA-LAML, and Leucegene datasets. Patients with high proportion of C5 cells or high C5 signature score have significantly worse overall survival than those with low proportion of C5 cells or low C5 signature score. Data from our center showed worse overall response rate to chemotherapy and overall survival in NM patients than CM patients. Prediction results from the ScFOCAL algorithm showed wide resistance to the frequently used drugs in hematopoietic malignancies including venetoclax, midostaurin, decitabine, and doxorubicin.

 

To validate whether CEBPA N-terminal frameshift mutation induces chemotherapy in AML. Molm-13 and THP-1 were used to construct CEBPA mutant cell lines. The truncated mutant of CEBPA typically caused by N-terminal frameshift mutation (P30), the wild-type CEBPA (OE), and the bZIP inframe mutant (CTM) were overexpressed respectively in Molm-13 and THP-1 cell lines. CCK-8 and colony formation assay showed significantly lower sensitivity of the P30 cells to a wide variety of chemotherapy drugs than OE and CTM cells. In vivo experiments using NSG mice confirmed the chemoresistance of P30 cells.

 

To explore the underlying mechanism of CEBPA N-terminal frameshift mutation induced chemoresistance, mRNA sequencing, cleavage under targets and agmentation, and assay for transposase-accessible chromatin with high-throughput sequencing were performed in OE, CTM, and P30 cells. The common upregulated genes in the P30 group enriched in the AMPK signaling pathway. The key AMPK component genes, PRKAA1, and PRKAB1 were also significantly upregulated in the P30 group. Since the activation of AMPK signaling was known to promote autophagy, a well-known mechanism for chemoresistance, we hypothesized that CEBPA N-terminal frameshift mutations induced multi-drug chemoresistance through the AMPK-autophagy axis. Western blotting, immunofluorescence, and transmissive electron micrography showed significantly stronger AMPK expression, phosphorylation, and mitochondrial autophagy in P30 cells compared to the OE and CTM cells. Inhibiting AMPK activity using the AMPK inhibitor, compound C, significantly inhibited the baseline autophagy level of P30 cells.

 

To test the potential of this mechanism to improve chemotherapy efficiency in AML patients carrying CEBPA N-terminal frameshift mutations, compound C and the autophagy inhibitor, chloroquine, were used in vitro and in vivo. CCK-8 assay showed that both compound C and chloroquine enhanced the cytotoxicity of chemotherapy drugs. In vivo administration of compound C and chloroquine in NSG mice extended survival both in single and in combination with chemotherapy drugs.

 

Taken together, CEBPA N-terminal frameshift mutation promotes AML chemoresistance via the AMPK-autophagy axis. Inhibiting AMPK signaling or autophagy can reverse this effect.

Ruoyang Shao, MD, PhD: No relevant conflicts of interest to declare.